Physician profile
Wesley Todd Brookover
NPI 1659457455
$12,972.38
in general payments reported to CMS, 2019-2025
50 companies · $2,079 in 2025
The $2,079 reported for 2025 was more than what 81% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,031 · 2020: $1,308 · 2021: $2,206 · 2022: $2,256 · 2023: $1,663 · 2024: $1,430 · 2025: $2,079.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,137 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,136.65 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,842.60 | 2019-2025 | Erleada, Carvykti, Rybrevant |
| Astellas Pharma US INC | $1,489.07 | 2019-2025 | Xtandi |
| Dendreon Pharmaceuticals LLC | $1,014.73 | 2019-2025 | Provenge |
| Pfizer INC. | $774.19 | 2019-2025 | |
| Urogen Pharma, INC. | $680.94 | 2021-2025 | Jelmyto |
| Coloplast Corp | $617.93 | 2019-2024 | Speedicath |
| Bayer Healthcare Pharmaceuticals INC. | $615.46 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $591.11 | 2020-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Tolmar Pharmaceuticals, INC. | $374.70 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $342.66 | 2023-2025 | Orgovyx, Gemtesa |
| Neotract INC. | $336.35 | 2019 | |
| Blue Earth Diagnostics | $324.09 | 2019-2025 | Posluma |
| Novartis Pharmaceuticals Corporation | $304.98 | 2022-2025 | |
| Procept Biorobotics Corporation | $304.54 | 2020-2024 | Aquabeam Robotic System, Aquabeam System |
| Astrazeneca Pharmaceuticals LP | $282.19 | 2021-2025 | Lynparza, Imfinzi |
Show all 48 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$340,127.28 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Brookover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.